Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data

Breast Cancer Research

Volumn 8, Issue 5, 2006, Pages

  Grigoriadis, Anita ^a   Mackay, Alan ^b   Reis Filho, Jorge S ^b   Steele, Dawn ^b   Iseli, Christian ^c   Stevenson, Brian J ^c   Jongeneel, C Victor ^c   Valgeirsson, Haukur ^b   Fenwick, Kerry ^b   Iravani, Marjan ^b   Leao, Maria ^a   Simpson, Andrew J G ^d   Strausberg, Robert L ^e   Jat, Parmjit S ^f   Ashworth, Alan ^b   Neville, A Munro ^a   O'Hare, Michael J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e J CRAIG VENTER INSTITUTE   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKERATIN 10; CYTOKERATIN 14; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 13; FIBROBLAST GROWTH FACTOR 4; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; KERATINOCYTE GROWTH FACTOR; NERVE GROWTH FACTOR BETA SUBUNIT; PERIOSTIN; RAB PROTEIN; RAL PROTEIN; RAP PROTEIN; RNA; SCLEROPROTEIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BASAL CELL; BREAST CARCINOMA; CANCER INFILTRATION; CELL ISOLATION; CELL POPULATION; CELL SPECIFICITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA MICROARRAY; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE TECHNOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MARKER GENE; MASSIVELY PARALLEL SIGNATURE SEQUENCING; MOLECULAR GENETICS; MYOEPITHELIUM CELL; NUCLEOTIDE SEQUENCE; PROGNOSIS; SEQUENCE ANALYSIS; TISSUE MICROARRAY; TREATMENT PLANNING; UNINDEXED SEQUENCE; UPREGULATION; VALIDATION STUDY; BREAST; BREAST TUMOR; CELL CULTURE; FEMALE; GENETIC TRANSCRIPTION; GENETICS; TUMOR CELL CULTURE;

BREAST; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELLS, CULTURED; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33750705865     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1604     Document Type: Article

References (59)

1. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
2. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116:340-350.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
6. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
7. Clarke C, Titley J, Davies S, O'Hare MJ: An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol 1994, 3:38-46.
8. O'Hare MJ, Ormerod MG, Monaghan P, Lane EB, Gusterson BA: Characterization in vitro of luminal and myoepithelial cells isolated from the human mammary gland by cell sorting. Differentiation 1991, 46:209-221.
9. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, et al.: Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003, 1:826-835.
10. Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, et al.: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 1999, 96:12589-12594.
11. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, et al.: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004, 64:3037-3045.
12. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K: A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001, 61:5697-5702.
13. Zucchi I, Mento E, Kuznetsov VA, Scotti M, Valsecchi V, Simionati B, Vicinanza E, Valle G, Pilotti S, Reinbold R, et al.: Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Natl Acad Sci USA 2004, 101:18147-18152.
14. Chang JC, Hilsenbeck SG, Fuqua SA: The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res 2005, 7:100-104.
15. Robison JE, Perreard L, Bernard PS: State of the science: molecular classifications of breast cancer for clinical diagnostics. Clin Biochem 2004, 37:572-578.
16. Shen D, He J, Chang HR: In silico identification of breast cancer genes by combined multiple high throughput analyses. Int J Mol Med 2005, 15:205-212.
17. van Ruissen F, Ruijter JM, Schaaf GJ, Asgharnegad L, Zwijnenburg DA, Kool M, Baas F: Evaluation of the similarity of gene expression data estimated with SAGE and Affymetrix GeneChips. BMC Genomics 2005, 6:91.
18. Brenner S, Johnson M, Bridgham J, Golda G, Lloyd DH, Johnson D, Luo S, McCurdy S, Foy M, Ewan M, et al.: Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol 2000, 18:630-634.
19. Brenner S, Williams SR, Vermaas EH, Storck T, Moon K, McCollum C, Mao JI, Luo S, Kirchner JJ, Eletr S, et al.: In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. Proc Natl Acad Sci USA 2000, 97:1665-1670.
20. ArrayExpress [http://www.ebi.ac.uk/arrayexpress/]
21. Iseli C, Stevenson BJ, de Souza SJ, Samaia HB, Camargo AA, Buetow KH, Strausberg RL, Simpson AJ, Bucher P, Jongeneel CV: Long-range heterogeneity at the 3′ ends of human mRNAs. Genome Res 2002, 12:1068-1074.
22. Jongeneel CV, Iseli C, Stevenson BJ, Riggins GJ, Lal A, Mackay A, Harris RA, O'Hare MJ, Neville AM, Simpson AJ, et al.: Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci USA 2003, 100:4702-4705.
23. Naef F, Huelsken J: Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks. Nucleic Acids Res 2005, 33:e111.
24. The R Project for Statistical Computing [http://www.rproject.org/]
25. Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article 3.
26. Bioconductor [http://www.bioconductor.org/]
27. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
28. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995, 57:289-300.
29. Draghici S, Khatri P, Bhavsar P, Shah A, Krawetz SA, Tainsky MA: Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res 2003, 31:3775-3781.
30. Onto-Express [http://vortex.cs.wayne.edu/ontoexpress]
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.
32. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, Dowsett M: Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006, 19:999-1009.
33. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75(NTR)) in normal, benign and malignant breast tissue. Mod Pathol 2006, 19:307-319.
34. Lehmann: Testing Statistical Hypothesis New York: Wiley; 1986.
35. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, et al.: A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005, 65:4059-4066.
36. Whitfield ML, George LK, Grant GD, Perou CM: Common markers of proliferation. Nat Rev Cancer 2006, 6:99-106.
37. Cheng JM, Ding M, Aribi A, Shah P, Rao K: Loss of RAB25 expression in breast cancer. Int J Cancer 2006, 118:2957-2964.
38. Newton G, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Lawler J: Characterization of human and mouse cartilage oligomeric matrix protein. Genomics 1994, 24:435-439.
39. Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, Khrebtukova I, Kuznetsov D, Stevenson BJ, Strausberg RL, Simpson AJ, et al.: An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res 2005, 15:1007-1014.
40. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, et al.: Multiple-laboratory comparison of microarray platforms. Nat Methods 2005, 2:345-350.
41. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL, Liu AY: Application of Affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 2005, 5:86.
42. Draghici S, Khatri P, Eklund AC, Szallasi Z: Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006, 22:101-109.
43. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003, 33:28-37.
44. Green AR, Green VL, White MC, Speirs V: Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 1997, 72:937-941.
45. Kothari MS, Ali S, Buluwela L, Livni N, Shousha S, Sinnett HD, Vashisht R, Thorpe P, Van Noorden S, Coombes RC, et al.: Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. Br J Cancer 2003, 88:1071-1076.
46. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
47. Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH: The S100A7-c-Jun activation domain binding protein 1 pathway enhances poor survival pathways in breast cancer. Cancer Res 2005, 65:5696-5702.
48. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
49. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001, 98:11462-11467.
50. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al.: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005, 65:4101-4117.
51. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002, 62:5358-5364.
52. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004, 24:3992-4003.
53. Sasaki H, Dai M, Auclair D, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y, Chen LB: Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients. Cancer Lett 2001, 172:37-42.
54. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 2003, 77:245-252.
55. Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G: Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005, 23:4695-4704.
56. Coleman RE: Conclusion: Bone markers in metastatic bone disease. Cancer Treat Rev 2006, 32(Suppl 1):27-28.
57. Segal E, Friedman N, Koller D, Regev A: A module map showing conditional activity of expression modules in cancer. Nat Genet 2004, 36:1090-1098.
58. Barsky SH: Myoepithelial mRNA expression profiling reveals a common tumor-suppressor phenotype. Exp Mol Pathol 2003, 74:113-122.
59. Polyak K, Hu M: Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 2005, 10:231-247.